Rationale and design of the CADENCE trial: evaluating sotatercept in Cpc-PH secondary to HFpEF

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Alessia Urbinati

New York (United States of America)

8 More presentations in this session

Presentation thumbnail

Discussant - Pharmacotherapy for heart failure (1)

Presentation thumbnail

Finerenone in patients with heart failure and diabetic kidney disease: comparison of mineralocorticoid receptor antagonists. FINARM study

Mr E. Boada Lincango (A Coruna, ES)

Abstract Slides Video

Presentation thumbnail

A novel, Pillar-GDMT score for prediction of all-cause mortality in patients with heart failure with reduced ejection fraction requiring heart failure hospitalisation

Doctor B. Muk (Budapest, HU)

Presentation thumbnail

SGLT2i and ARNI improve long-term heart failure outcomes: a multi-state model analysis from a real-world southeast asian cohort

Doctor P. Amornritvanich (Bangkok, TH)

Abstract Slides Video

Presentation thumbnail

Comparison of the effect of the rapid up-titration programme and the standard care on therapy optimisation at a heart failure outpatient clinic in real-world clinical practice

Doctor F. Banfi-Bacsardi (Budapest, HU)

Abstract Slides Video

Access the full session

Session thumbnail

New perspectives in cardiology (4) - Pharmacotherapy for heart failure (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion

Congress Presentation

The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources